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Abstract
Phosphorylation-dependent protein–protein interaction has rarely been targeted in medicinal chemistry.
Thymoquinone, a naturally occurring antitumor agent, disrupts prephosphorylated substrate recognition
by the polo-box domain of polo-like kinase 1, a key mitotic regulator responsible for various
carcinogenesis when overexpressed. Here, crystallographic studies reveal that the phosphoserine/
phosphothreonine recognition site of the polo-box domain is the binding pocket for thymoquinone and its
analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a
slow but noncovalent binding mode. A conserved water bridge and a cation−π interaction were found as
their competition strategy against the phosphate group. This mechanism sheds light on small-molecule
intervention of phospho-recognition by the polo-box domain of polo-like kinase 1 and other phosphobinding proteins in general.
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ABSTRACT: Phosphorylation-dependent protein-protein interaction has rarely been targeted in medicinal chemistry. Thymoquinone, a naturally occurring antitumor agent, disrupts pre-phosphorylated substrate recognition by the polo-box domain of polo-like
kinase 1, a key mitotic regulator responsible for various carcinogenesis when over-expressed. Here, crystallographic studies reveal
that the phosphoserine/phosphothreonine recognition site of the polo-box domain is the binding pocket for thymoquinone and its
analogue poloxime. Both small molecules displace phosphopeptides bound with the polo-box domain in a slow but non-covalent
binding mode. A conserved water bridge and a cation-π interaction were found as their competition strategy against the phosphate
group. This mechanism shed lights on small-molecule intervention of phospho-recognition by the polo-box domain of polo-like
kinase 1 and other phospho-binding proteins in general.

Thymoquinone (TQ) is the main therapeutic ingredient extracted from Nigella sativa with medical application for centuries.1 Its
anti-proliferative effect covers a wide range of tumor cell lines and in vivo models.1-9 Its safety was underscored in the recent Phase
1 clinical trial.10 Multiple molecular pathways have been proposed to account for TQ-induced apoptosis and cell cycle arresting at
G0/G1,3 G1,4 early G1/S5 and G2/M3 phases, involving mitotic regulators such as p53 protein, nuclear factor-kappa B and caspase-8.79
However, the molecular targets of TQ remained elusive until the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was proposed.11
Plk1 is an essential promoter of M Phase progression and its unchecked expression at G2/M Phase12 leads to carcinogenesis in
many TQ-sensitive tumor types.2, 6, 7, 13 While a number of inhibitors were developed to disrupt the kinase domain of Plk1,14 its noncatalytic PBD emerged as an alternative target. PBD guides the catalytic domain to pre-phosphorylated substrates by recognizing a
Ser-pSer/pThr core motif15 and, as shown by Reindl et al.,11 TQ disrupts this process, delocalizes Plk1 and eventually arrests the
cell cycle.
Though a few non-peptidic inhibitors against Plk1-PBD have been identified,11, 16, 17 how TQ or any of them blocks the phosphosubstrate recognition remained unknown due to the undetermined inhibitor binding site and the mechanism.11, 18 Covalent modification was proposed based on the on-set time dependency of TQ11 and the fact that the quinone ring has Michael acceptor carbons
capable of reacting with thiol groups on surface cystein residues.
Moreover, Reindl et al. found the multiple targeting of phospho-recognition proteins by TQ, including Chk2 FHA domain and
Pin1 WW domain which recognize pSer/pThr motif, and Src homology 2 (SH2) domain of STAT3 which binds to pTyr epitope.11
This may suggest a specific binding mode of TQ to phospho-recognition sites. Targeting phospho-signaling by blocking pTyr recognition remains challenging to date.19 Besides, there's no definitive mechanistic elucidation to the small-molecule inhibition of
PBD, one of the rarely tapped pSer/pThr binding domains. Structural evidence of TQ inhibiting phospho-recognition by Plk1 PBD
may explain the time-dependency and reveal a mechanism of small molecule intervention of phospho-recognition.
In this work we present a TQ-complexed Plk1-PBD crystal structure (PBDT, 2.75 Å; crystallographic data in Supplementary Table S1). We tried to soak poloxin, a known Plk1-PBD inhibitor,11 into PBD crystals but only found electron density for the oxime
fragment of poloxin (PBDP, 1.93 Å; crystallographic data in Supplementary Table S1). We therefore named this TQ analogue poloxime (PXE), a combination of “poloxin” and “oxime”. As expected, PXE is a hydrolysis product of poloxin, confirmed with liquid chromatography-mass spectrometry (Supplementary Figure S1a-b). The lower occupancy of PXE may explain its higher Bfactor than that of TQ (Supplementary Table S1). We further determined a native PBD crystal structure (PBDApo, 1.95 Å; crystallographic data in Supplementary Table S1).
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Figure 1. (a–b) Ribbon diagram of PBDT chain A (Lemon) and PBDP chain A (Pink). Residues around TQ (Yellow) and PXE (Magenta)
are presented. Glycerol molecules are shown in grey and water molecules as red balls.2mFo-DFc electron density maps (blue wire mesh)
of TQ and PXE are contoured at 1 σ. (c) PBDT chain A is superimposed onto Protein Data Bank entry 3BZI, both colored by secondary
structure (α-helix: blue, β-sheet: coral and others: white). TQ (Yellow) and a glycerol molecule (Grey) are shown. The phosphopeptide in
3BZI is shown in dark green (Non-carbon atoms are colored as N: blue, O: red and P: magenta). Hydrogen bonds between the phosphate
and the Lys540-His538 pincer are shown in dotted lines. Red balls represent water molecules in 3BZI.

PBDT and PBDP pinpointed the inhibitor binding site: the phosphate group recognition site between the two polo boxes of the
PBD, each consisting of an α helix and a β sheet (Figure 1a–b). This pocket consists of a hydrophobic half (Val411, Trp414,
Leu490 and Leu491) and a positively charged half (His538, Lys540 and Arg557) where the Lys540-His538 pincer clinches phosphopeptides by the phosphate (Figure 1c).20 A glycerol molecule is found near the bound ligands, occupying the Ser-1 position for
phosphopeptide binding, which is observed in other PBD crystal structures as well.15
Pre-phosphorylation of Plk1 substrates (e.g. p-Cdc25c, Figure 1c) is critical for the PBD recognition15, 20 and accounts for superior binding affinity by several orders of magnitude compared to their non-phosphorylated versions, which was found almost nonbinding by Huggins et al. using isothermal titration calorimetry.21 However, a PBD crystal structure with a non-phosphorylated
peptide is available14. This can be explained by the law of mass: the co-crystallography is done with high concentrations of both the
protein and the peptide. Since the phosphate group functions as a turnkey in phosphorylation-dependent signaling pathways, the
PBDT structure suggests that TQ jams the keyhole, preventing Plk1 from recognizing its mitotic substrates via PBD, and may subsequently promote cell-cycle arrests and apoptosis. This corroborates with the G2/M Phase arrests in both TQ-centered3 and Plk1centered studies12.
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Figure 2. (a-b) TQ (Yellow) and PXE (Magenta) in contact with a structural water (W1), respectively. TQ/PXE-bound structures (Lemon
and Pink) are superimposed onto PBDP chain B (White) as a native structure. Atoms are colored by model except non-carbon atoms of the
PBDT/PBDP side chains (N: blue, O: red). Glycerol molecules are CPK colored. Hydrogen bonds are given as red dashed lines. Arrows
show the shift of Leu491.

The binding of TQ and PXE has no apparent disruption of PBD compared to the native structure except for a ~2 Å positional
shift in Leu491 side chain (Arrow, Figure 2a–b). In fact, the entire Leu491-Leu492 back bone was slightly pushed away to allow
entry of two interfacial water molecules (W8 and W9) in PBDP or PBDT. Lys540 has close contact with both ligands while the imidazole ring of His538 is slightly turned but not close enough (>3.5 Å to the nearest carbon of TQ/PXE) to make interaction. What's
more, we found the pocket extensively hydrated by crystallographic water molecules (W1–W11, Figure 2a-b), which makes no
extra space for bulk solvent (Figure S3a). The binding of TQ/PXE is in effect a displacement of several crystallographic waters
(W5–7). When bound, PXE is buried in a network of structural waters (Figure S3c), which should be the same case of TQ binding
but water molecules can hardly be identified due to the lower resolution (Figure S3b).
Reindl et al. did not observe a covalently bound inhibitor to PBD with mass spectrometry so as to explain time-dependent inhibition.11 Neither does TQ/PXE have covalent bonds with PBD as shown by the crystal structures nor do they mimic a charged phosphate. The question becomes what directed the binding of TQ/PXE to the phosphate binding site and why time-dependency. A fluorescence polarization based assay11 was used to characterize TQ and PXE’s binding kinetics by tracing the unbound PBD with fluorescently labeled phosphopeptide. The IC50 values of both TQ and PXE inhibiting the phosphopeptide binding were tracked (Supplementary Figure S2). The dropping of IC50s slowed down remarkably after a quick slump and the Hill slope values were converging to 1(Supplementary Table S2a, 2c). These indicate competitive binding instead of inactivation due to covalent modification. We
initiated dissociation of pre-incubated TQ/PXE-PBD with dithiothreitol, which neutralizes TQ and PXE containing Michael acceptors. However, due to the limited time frame we weren't able to see complete dissociation of PXE, while TQ did not display significant dissociation (Supplementary Table S2b, 2d). The dissociation of PXE casts doubt on covalent modification and supports competitive binding as a viable theorem. The glycerol molecule adjacent to TQ and PXE has contacts with both ligands but glycerol, up
to 30% in the buffer, had no effect in neither the peptide binding or the TQ/PXE inhibition (Data not shown).
A recent study of shielded hydrogen bonds as the determinant of binding kinetics may uncover the mechanism of the slow binding of TQ and PXE.22 In their work the almost buried polar atoms (ABPA) of the receptor are found responsible of slow ligand
binding as the solvent accessible surface area of the ABPA (A0) is less than 10 Å2 and the binding site is concave (∆A<0, A0 decreases as the probe size increases). Such slow-dissociating ligand-receptor pair is exemplified by biotin-streptavidine of which the
dissociation rate constant can be 100 fold smaller23 than that of TQ-PBD, presumably because of those water-shielded hydrogen
bonds.
The structural feature of the PBD binding pocket is a similar case as a structural water (W1, Figure 2) serves as an ABPA (A0 =
2.96Å2, ∆A<0) which, once with a hydrogen bond with TQ/PXE, is completely shielded from bulk solvent (A0 = 0). The V-shaped
concave pocket only allows the presence of few adjacent crystallographic waters (W2, W8 and W9) thus greatly reducing any di-
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electric effect by bulk solvent and strengthening the hydrogen bonding between the W1 and TQ/PXE. Both the narrow pocket and
TQ/PXE are steric impediment themselves, preventing bulk solvent from coming in to contact with W1 before ligand dissociation.
Similarly, the kinetic barrier of TQ/PXE association should largely come from the dissociation of W5, which shields W1 from bulk
solvent as well. In fact, as aforementioned, the narrow and deep pocket doesn't have space for bulk solvent at all (Supplementary
Figure S3a), which means all three structural water molecules (W5–W7, Figure 2a-b) have to dissociate before TQ/PXE can access;
accordingly, TQ/PXE has to move out of the pocket before water can refill it. Such empty-pocket transition state must be energetically unfavorable and kinetically penalized. Consistently, due to the smaller size of water than TQ/PXE, steric impediment is less
significant for water, which explains the much slower dissociation of TQ/PXE than their respective association.
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Figure 3. (a) Root mean square fluctuation of crystallographic waters averaged over the first 4 ns simulation. Dashed line represent y=3.0.
W1 is shown as a red square. (b) W1 (as ball and stick) and nearby residues (as cylinders), added with hydrogen and energetically minimized. Atoms are CPK colored. Blue and red dashed lines represent hydrogen bonds between W1 and Asn533/Val411, respectively, of
which the lengths are plotted as radial distribution function in (c), where the blue and red curves peak at the most probable radius within
the 4 ns.

In addition, we assessed the mobility of crystallographic waters with a 6 ns molecular dynamics simulation to verify the role of
W1 as a structural water that needs to be treated as a part of the receptor. We tracked the trajectory and found W1 showing little
movement during the first 4 ns, together with other 2 waters below 3 Å of root mean square fluctuation (RMSF) (Figure 3a). W1,
the only conserved water in the phosphate binding pocket, oscillated between Asn533ND2 (a hydrogen donor) and Val411O (a
hydrogen acceptor). Their bond lengths are demonstrated in the plot of radial distribution function (RDF): the red peak (2.75 Å) for
the most-likely distance between W1O and Val411O, and the blue peak (3.15 Å) for that of W1O and Asn533ND2 (Figure 3b, 2c).
Such arrangement enables W1 to bridge the binding of either a hydrogen acceptor (carbonyl O7of TQ) or a potential hydrogen donor (PXE's oxime O13): W1 makes two hydrogen bonds in both cases, one with the receptor, the other with the ligand. Additionally, W1 is buried deeply in the pocket and not available in phosphopeptide positioning. TQ/PXE are capable of penetrating the hydrogen bond network made by crystallographic waters by slowly displacing them and eventually anchor themselves on the conserved W1, while a phosphate group can only recruit waters with much higher mobility.21
Both TQ and PXE lack the negative charges of a phosphate group which allows it to be attracted by the protonated Lys540. They
nevertheless overlap with the phosphate when the protein structures are superimposed and are particularly close to Lys540. We
suspected there is a cation- interaction between the protonated lysine Nζ and TQ/PXE's cross-conjugated systems, which may
represent another strategy for the small molecules to compete with phosphopeptides.
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Figure 4. The shortest inter-molecular distances between Lys540+ and TQ(a)/PXE(b) are represented as dashed lines. Atoms are CPK
colored.

Table 1. MP2 calculated interaction energies (kcal/mol)
Lys540-TQ
6-31G(0.25)
6-311+G()
Lys540-PXE
6-31G(0.25)
6-311+G()

EHFa

EMP2a

Ecorrb

-0.89
-0.30

-6.52
-5.77

-5.63
-5.47

-0.09
0.72

-8.37
-7.62

-8.28
-8.34

a

Gas-phase intermolecular interaction energies (in kcal/mol) at the MP2 level (EMP2) and HF level (EHF) after BSSE correction. b The dispersion energy was defined as Ecorr = EMP2 - EHF.
Since the current molecular mechanics force fields do not explicitly account for cation- interaction and likely the cause of both
TQ and PXE being drawn to Arg557 during MD simulations of PBDT and PBDP respectively (data not shown), we turn to quantum
mechanical calculations to see if TQ or PXE nevertheless make use of the Lys540 albeit lacking net negative charges. Lys540Nζ+
is located on top of C6 in the TQ/PXE-bound structures, and thus Nζ+-C6 is nearly vertical to the -C2=C1-C6=O7/N7- plane (Figure
4a-b). Considering that C6 is a local geometric centre of the cross-conjugated systems consisting two alkenes (C4=C5 and C1=C2),
and a carbonyl/oxime group, Nζ+ is on a favourable spot for making cation-π interaction.We did ab initio quantum mechanical
calculations of interaction energy, defined as the energetic difference between the complex (Ecomplex) and the monomers (Eligand and
Eprotein), at Hartree-Fock (HF) and the MP2 levels using 6-31G (0.25) and 6-311+G() basis set. The basis set superposition error
(BSSE) was corrected using the Boys and Bernardi counterpoise method.24 The calculated interaction energies (Table 1) are of significant magnitude, suggesting that the protonated Lys540 remarkably stabilizes TQ/PXE-PBD complexes. Comparison of MP2
and HF interaction energies shows a substantial correlation correction, which indicates that in addition to electrostatic interactions,
dispersion energies (electron correlation effect) contribute substantially to the cation-π interaction. The reduced dielectric effect due
to the lack of nearby bulk solvent should be favourable of such interaction. This solvent shielded interaction should have a similar
effect to the binding kinetics just as the solvent shielded hydrogen bond.
A number of phospho-recognition protein has emerged with a variety of functions with regard to phosphorylation-dependent signaling and cell cycle control, including 14-3-3,25 BRCA1 carboxyl terminal domains,26 FHA domains27 and the aforementioned
Pin1 and Plk1-PBD domains which TQ binds to. Since these pSer/pThr binding proteins have lysine and/or arginine in their phos-
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pho-recognition pockets as Plk1 PBD does,20 such cation-π interaction may be a general phenomenon and explains the nonspecificity of TQ.
Although having potentially reactive α, β-unsaturated carbons, TQ is the only small-molecule inhibitor of pSer/pThr/pTyr recognition with actual therapeutic application in intervening cell cycle signalling to our knowledge. Unlike phosphonate, sulphonate or
carboxylic compounds as phosphate mimics which have poor membrane permeability, TQ is moderately hydrophobic and bears
zero net charge, yet utilizing the targets' structural features for phosphate-binding just the same. In fact, other PBD inhibitors may
use the same strategy since they have substructures that resemble TQ. A pan-specific PBD inhibitor16 has a cross-conjugated hexatomic ring system with a carbonyl terminus and a large group similar to the isopropyl group of TQ. Purpurogallin17, another PBD
inhibitor with a cross-conjugated system in a heptatomic ring, similarly has a carbonyl terminus and a combined ring at the position
of the isopropyl group of TQ. They could adopt the same orientation of TQ/PXE when binding to PBD and have interactions with
the structural water and the Lys540. As the candidate pool of PBD inhibitors expands, we will learn more about the structural basis
of phospho-recognition inhibition of PBD. The complex structures herein offer a new perspective of the energetic nature of
TQ/PXE's competition of phosphopeptide binding to Plk1 PBD. The phospho-mimicry mechanism may benefit medicinal design
targeting PBD and other phospho-binding domains in general.

METHODES
Plk1-PBD constructs, residue range 326-603 for assay and residue range 367-603 for crystallography, were cloned, expressed and purified.
Crystallization was carried out by vapor diffusion at 18 ºC in 1.4 M sodium potassium tartrate, 50 mM MES, pH 6.5, and 100 mM Hepes,
pH 6.0. TQ/PXE were soaked into the crystals. Diffraction data sets were collected at wavelength 0.98 Å, 100 k, at the Beamline 17U,
Shanghai Synchrotron Radiation Facility (SSRF). Structure was solved by molecular replacement using Protein Data Bank entry 1UMW as
search models. Data collection and refinement statistics are reported in Table S1. Full details are given in the Supporting Information online.
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